| Aisha Simpson, WHNP | |
|
404 Fox Hunt Dr, Bear, DE 19701-2538 | |
| (302) 652-2455 | |
| (302) 322-6251 |
| Full Name | Aisha Simpson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Women's Health |
| Location | 404 Fox Hunt Dr, Bear, Delaware |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417399023 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LW0102X | Nurse Practitioner - Women's Health | LH-0000202 (Delaware) | Primary |
| Entity Name | Westside Family Healthcare, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952303695 PECOS PAC ID: 6800706599 Enrollment ID: O20040716000419 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.
A team of scientists led by the University of Southampton has taken an important step forward in research efforts that could one day lead to an effective vaccine against the world's deadliest infectious disease.
Advances in the treatment of Multiple Sclerosis have been good news for patients, but side effects and risks mean that an active management strategy and constant monitoring are essential.
Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.
› Verified 6 days ago
| Entity Name | Planned Parenthood Of Delaware, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124033865 PECOS PAC ID: 6406860154 Enrollment ID: O20060201000667 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.
A team of scientists led by the University of Southampton has taken an important step forward in research efforts that could one day lead to an effective vaccine against the world's deadliest infectious disease.
Advances in the treatment of Multiple Sclerosis have been good news for patients, but side effects and risks mean that an active management strategy and constant monitoring are essential.
Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aisha Simpson, WHNP Po Box 151, New Castle, DE 19720-0151 Ph: (302) 652-2455 | Aisha Simpson, WHNP 404 Fox Hunt Dr, Bear, DE 19701-2538 Ph: (302) 652-2455 |
News Archive
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.
A team of scientists led by the University of Southampton has taken an important step forward in research efforts that could one day lead to an effective vaccine against the world's deadliest infectious disease.
Advances in the treatment of Multiple Sclerosis have been good news for patients, but side effects and risks mean that an active management strategy and constant monitoring are essential.
Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.
› Verified 6 days ago
Ms. Amanda Jennifer Bostick, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 121 Becks Woods Dr Ste 100, Bear, DE 19701 Phone: 302-261-5600 Fax: 302-836-4302 | |
Sarah Grove, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 404 Fox Hunt Dr, Bear, DE 19701 Phone: 302-652-2455 Fax: 302-322-6251 | |
Deborah F Bryant, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 404 Fox Hunt Dr, Fox Run Shopping Center, Bear, DE 19701 Phone: 302-836-2864 Fax: 302-918-3219 | |
Miss Leslie Yvette Sterling, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 53 Perth St, Bear, DE 19701 Phone: 267-456-9391 | |
Anita K Kombo, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1545 Pulaski Hwy, Bear, DE 19701 Phone: 302-832-8701 | |
Vinneta Shorter, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 121 Becks Woods Dr Ste 200, Bear, DE 19701 Phone: 302-834-7676 | |
Mr. Ernest Tamajong, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2500 Wrangle Hill Rd, Ste 220, Bear, DE 19701 Phone: 302-437-6833 Fax: 302-455-8550 |